Comparative Pharmacology
Head-to-head clinical analysis: AFREZZA versus OSENVELT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AFREZZA versus OSENVELT.
AFREZZA vs OSENVELT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhaled human insulin that lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin binds to the insulin receptor, activating tyrosine kinase activity leading to downstream metabolic effects.
Selective allosteric inhibitor of the sodium-glucose cotransporter 2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose.
Inhaled powder; initial dose: 4 units per inhalation at each meal, titrated based on blood glucose; maximum 48 units per meal. Administer via Afrezza Inhaler.
200 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours for insulin component; clinical context: duration of glucose-lowering effect may extend beyond due to receptor binding.
Terminal elimination half-life is approximately 12-15 hours, supporting once-daily dosing.
Renal: approximately 60-80% as unchanged drug and metabolites (insulin degradation products). Biliary/fecal: minor, <20%.
Renal excretion of unchanged drug accounts for 30-40% of elimination; fecal/biliary excretion accounts for 55-65%.
Category C
Category C
Antidiabetic Agent
Antidiabetic Agent